Adlai Nortye Ltd.
(NASDAQ: ANL)
|
5:30 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $3.64 | Change: +0.01 | %Change: +0.14% | Volume: 1,611 |
Open: | $ 3.48 | Volume: | 1,611 | |
---|---|---|---|---|
High: | $ 3.64 | Yield(%) | 0.00 | |
Low: | $ 3.48 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 341.11M | |
EPS ($) | -0.91 | Shares Out: | 93.71M |
% Price Change (last 4 weeks): | -42.48 |
---|---|
% Price Change (last 13 weeks): | -61.94 |
% Price Change (last 26 weeks): | -60.62 |
% Price Change (last 52 weeks): | n/a |
% Price Change (year to date): | -59.51 |
Return on Equity (%): | n/a |
---|---|
Return on Assets (%): | -103.34 |
Return on Invested Capital (%): | n/a |
Gross Profit Margin (%): | 55.56 |
---|---|
Net Profit Margin (%): | -2097.42 |
Operating Profit Margin (%): | -1368.82 |
|
|
50-day Moving Average: | $8.31 |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | 15,781 |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $3.40 |
Ask: | $3.99 |
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
|
Adlai Nortye Ltd.
Building 6 & 8 1008 Xiangwang Street Yuhang District Hangzhou ZH 311100 Phone: 86.571.289.8385 Fax: n/a http://www.adlainortye.com |
Earnings (1year) ($): | n/a |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 0.72 |
Cash Flow ($): | -1.09 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 78.00 |
Price/Book (x): | 12.53 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 2.01 |
---|---|
Current Ratio (x): | 2.01 |
LT Debt/Equity (x): | 0.59 |
Total Debt/Equity (x): | 39.73 |